查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995483

D-二聚体检测市场：2026-2032年全球市场预测（按检测类型、技术、检体类型、应用和最终用户划分）

D-dimer Testing Market by Test Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，D-二聚体检测市场价值将达到 16.5 亿美元，到 2026 年将成长至 17.4 亿美元，到 2032 年将达到 25.4 亿美元，复合年增长率为 6.33%。

主要市场统计数据
基准年 2025 16.5亿美元
预计年份：2026年 17.4亿美元
预测年份 2032 25.4亿美元
复合年增长率 (%) 6.33%

这篇重点介绍说明了临床需求、技术进步和操作要求如何改变医疗保健环境中的 D-二聚体诊断过程。

D-二聚体检测已成为现代诊断流程中不可或缺的一部分，为急诊、住院病房和门诊的临床决策提供支援。 D-二聚体检测最初是作为检测纤维蛋白降解产物而开发的，随着检测技术、快速照护现场（POC​​）平台和综合临床演算法的进步，其应用也日益广泛。本文概述了D-二聚体诊断对医疗专业人员和相关人员的临床应用效用、营运影响和策略意义。

临床演算法、技术创新和不断变化的报销趋势如何重新定义 D-二聚体检测在诊断和患者管理中的应用。

由于临床、技术和政策等多面向因素的共同作用，D-二聚体检测的现状正经历着变革性的转变。临床上，更新的诊断流程强调风险分层和选择性影像检查，更依赖高灵敏度检测方法，并要求结果解读的一致性。这促使各医疗机构制定标准化的检测通讯协定，并在相关的患者群体中验证检验效能。同时，检测化学和自动化技术的进步提高了分析准确性，从而降低了检测阈值，并提高了血栓性疾病的阴性预测值。

2025 年美国关税政策变更对营运和采购的影响，以及这些变化如何影响诊断供应链的韧性和筹资策略。

2025年美国关税调整和贸易政策转变的累积影响正在重塑D-二聚体检测相关诊断设备和耗材的筹资策略。试剂、仪器组件和完整诊断平台的进口成本不断上涨，迫使检查室和医疗系统重新思考其采购方式、物流规划以及供应商多元化的努力。对于依赖国际供应链取得试剂组和专用检测组件的机构而言，这些商业性压力尤其严峻，导致它们更加重视库存管理和合约重新谈判。

详细的細項分析表明，测试类型、检测技术、检体基质、临床环境和应用如何独特地影响采用趋势和产品策略。

细分市场层面的趋势揭示了每种检测类型、技术、检体类型、最终用户和应用的不同价值来源，这些价值来源共同影响临床应用和商业性定位。就检测类型而言，检查室检测和即时检测 (POC) 解决方案之间已形成清晰的二分法，从而形成了不同的应用场景。集中式检查室平台优先考虑处理能力、分析准确性和与实验室资讯系统的集成，而 POC 解决方案则强调快速出结果、便携性以及直接向临床医生呈现结果。就技术而言，化学冷光免疫检测法凭藉其自动化工作流程和高灵敏度，常用于高通量检查室。酵素免疫分析法(ELISA) 为专业检测和实验室研究提供了柔软性。萤光免疫分析支援紧凑、高灵敏度的系统，适用于患者现场使用和中心检查室部署。在优先考虑简便性和成本效益的情况下，乳胶凝集测试仍然非常重要。

影响美洲、欧洲、中东和非洲以及亚太地区采用、监管和筹资策略的区域趋势和市场驱动因素

区域趋势对关键地区D-二聚体检测解决方案的需求模式、监管预期和竞争格局的形成至关重要。美洲地区的特点是临床应用日益普及，急诊医学领域越来越重视照护现场检测，以及支付方对成本效益和临床疗效的要求日益提高。该地区的实验室和医院通常寻求兼具检测性能和营运效率的整合解决方案，而製造商则优先考虑符合国家标准，以促进市场准入。

竞争格局分析，重点在于成熟公司、专业开发公司和即时照护创新者如何透过技术、伙伴关係和证据产生来实现差异化。

D-二聚体检测市场由成熟的诊断公司、专业检测开发商和新兴的即时检测（POC​​T）参与企业之间的竞争所构成。成熟的製造商凭藉其在临床检查室的良好口碑、丰富的试剂产品组合以及支援高通量中心检测的全球服务网络，保持强大的市场竞争力。这些成熟企业充分利用其与检查室自动化和资讯系统整合的能力作为竞争优势，同时不断投资改进检测性能，以巩固其在医院系统和参考实验室的地位。

诊断试剂製造商和医疗保健提供者的具体策略重点，以最大限度地提高 D-二聚体检测的临床应用、供应弹性和商业性影响。

产业领导企业应优先考虑一系列切实可行的策略，使商业性执行与临床影响和营运实际情况相符。首先，他们应投资于有针对性的临床证据项目，量化特定D-二聚体检测对患者诊疗路径、影像检查利用率和住院时长等指标的影响。这些研究应结合具体情境，并与最终使用者合作设计，以确保其相关性和可靠性。其次，他们应开发灵活的商业模式，降低推广应用的资金门槛，例如试剂租赁协议、基于结果的定价或基于订阅的数据分析和支援服务。这些模式在提高可近性的同时，也能让供应商的奖励与检查室的效能和运转率一致。

研究采用严谨的混合方法，结合对现场相关人员的访谈、对临床文献的回顾以及交叉检验的分析方法，以产生实用的诊断见解。

本研究整合了一级资讯来源和二级资讯来源资料，以确保研究的严谨性和相关性。一级资讯来源包括对实验室主任、临床病理学家、急诊医生、采购负责人和产品经理等利益相关者的访谈，并辅以现场相关人员，以了解工作流程的限制和推广应用的障碍。透过这些直接参与，我们获得了关于实际检测效能、预期回应时间和采购决策标准的定性见解。第二手资料包括同行评审的临床文献、监管文件、医疗设备使用手册以及公开的临床指南，这些资料提供了有关检测的效用和推荐诊断流程的资讯。

一项权威的综合分析重点阐述了临床价值、营运韧性和互通性解决方案如何决定 D-二聚体诊断生态系统的长期成功。

这项综合分析强调，D-二聚体检测在临床需求、技术创新和营运决策这三大要素的交汇点上占据着策略性地位。高灵敏度检测和快速照护现场方案并非相互排斥，而是相辅相成，从而能够实现循序渐进的诊断方法，使分析能力与临床需求相符。随着支付方和医疗服务提供者将重点放在以价值为导向的医疗和高效的资源利用上，证明D-二聚体检测如何减少不必要的影像检查并简化患者就诊流程的证据，将在塑造其应用模式方面发挥关键作用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 D-二聚体检测市场（依检测类型划分）

  • 检查室基地
  • 护理点

第九章：D-二聚体检测市场：依技术划分

  • 化学冷光免疫检测
  • 酵素免疫分析法
  • 萤光免疫分析
  • 乳胶凝集测试

第十章检体类型分類的D-二聚体检测市场

  • 电浆
  • 血清
  • 全血

第十一章：D-二聚体检测市场：依应用领域划分

  • 瀰漫性血管内凝血
  • 中风
  • 静脉血栓栓塞症

第十二章：D-二聚体检测市场：依最终用户划分

  • 门诊手术中心
  • 诊断检查室
  • 医院

第十三章：D-二聚体检测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：D-二聚体检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：D-二聚体检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国D-二聚体检测市场

第十七章：中国D-二聚体检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • DiaSorin SpA
  • Instrumentation Laboratory Company
  • Ortho Clinical Diagnostics Inc.
  • Roche Diagnostics GmbH
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-FB6C9E792A6C

The D-dimer Testing Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.74 billion in 2026, with a CAGR of 6.33%, reaching USD 2.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.74 billion
Forecast Year [2032] USD 2.54 billion
CAGR (%) 6.33%

A focused introduction explaining how clinical necessity, technological advances, and operational demands are reshaping D-dimer diagnostic pathways in care settings

D-dimer testing has become an essential element of modern diagnostic pathways, informing clinical decision-making across emergency departments, inpatient wards, and ambulatory settings. Initially developed as a laboratory assay to detect fibrin degradation products, D-dimer testing has evolved in parallel with advances in assay technology, rapid point-of-care platforms, and integrated clinical algorithms. This introduction outlines the clinical utility, operational implications, and strategic relevance of D-dimer diagnostics for healthcare providers and industry stakeholders.

Clinically, elevated D-dimer levels remain a sensitive indicator for thrombotic events such as venous thromboembolism and are used to triage patients for further imaging or anticoagulation therapy. Over time, the role of the test has broadened to include screening for disseminated intravascular coagulation and adjunctive evaluation of stroke patients. From an operational perspective, the availability of both laboratory-based assays and rapid point-of-care options has created new choices for care pathways where speed and decentralization of testing influence throughput and clinical outcomes. As a result, hospital laboratories, diagnostic centers, and ambulatory surgical units must balance analytical performance with turnaround time and workflow integration.

Strategically, industry participants and clinical leaders are navigating an environment shaped by changing reimbursement paradigms, evolving clinical guidelines, and technology-driven differentiation. Innovations in assay chemistries and automation are redefining performance benchmarks, while emerging point-of-care solutions are challenging traditional centralized testing models. This section frames the subsequent deeper analysis by highlighting the clinical drivers, technological enablers, and institutional considerations that make D-dimer testing a focal point for diagnostic strategy and investment.

How clinical algorithms, technological innovation, and evolving reimbursement dynamics are collectively redefining diagnostics and patient management with D-dimer testing

The landscape of D-dimer testing is experiencing transformative shifts driven by converging clinical, technological, and policy forces. Clinically, updated diagnostic algorithms emphasize risk stratification and selective imaging, increasing reliance on high-sensitivity assays and consistent result interpretation. This creates pressure to standardize testing protocols across institutions and to validate assay performance within relevant patient cohorts. Simultaneously, improvements in assay chemistries and automation have elevated analytical precision, enabling lower detection thresholds and improving negative predictive value for thrombotic conditions.

On the technology front, the proliferation of rapid point-of-care platforms is enabling diagnostic decentralization and facilitating decision-making at the bedside or in ambulatory settings. These devices reduce time-to-result and can influence patient flow, particularly in emergency departments where timely disposition is critical. Moreover, advances in chemiluminescence immunoassays, fluorescence immunoassays, and enzyme-linked immunosorbent approaches are generating differentiated value propositions for central laboratories, whereas latex agglutination methods continue to offer cost-effective alternatives in specific contexts.

Policy and reimbursement landscapes are also shifting, with payers and regulators increasingly focusing on evidence of clinical utility and cost-effectiveness. These changes favor integrated diagnostic solutions that demonstrably reduce unnecessary imaging and downstream costs. As a result, manufacturers and clinical labs are investing in real-world evidence generation and collaborative studies to validate diagnostic pathways. Together, these clinical, technological, and policy shifts are redefining competitive dynamics and creating opportunities for solutions that blend analytical robustness with operational agility.

Assessing the operational and procurement consequences of US tariff shifts in 2025 and how they are driving supply chain resilience and sourcing strategies for diagnostics

The cumulative effect of tariff adjustments and trade policy shifts in the United States during 2025 is reshaping procurement strategies for diagnostic equipment and consumables connected to D-dimer testing. Heightened import costs for reagents, instrumentation components, and finished diagnostic platforms have prompted laboratories and health systems to reassess sourcing approaches, logistics planning, and supplier diversification efforts. These commercial pressures are particularly acute for facilities that rely on international supply chains for reagent kits and specialized assay components, leading to an increased focus on inventory management and contract renegotiation.

In response to tariff-related cost burdens, many stakeholders are pursuing operational adaptations such as consolidating procurement volumes with preferred suppliers, exploring domestic manufacturing partnerships, and prioritizing assays that minimize consumable complexity. Clinical laboratories are evaluating the total cost of ownership more rigorously, weighing instrument amortization, reagent shelf-life, and service support against unit test costs. These dynamics have also encouraged vendors to introduce bundled solutions and flexible commercial models, including reagent rental agreements and performance-based contracts that mitigate up-front capital exposure.

The net effect on clinical delivery is a heightened emphasis on resilience and supply-chain transparency. Health systems are instituting dual-sourcing strategies and expanding in-house validation capabilities to reduce service disruption risk. At the same time, vendors are accelerating localization efforts and exploring alternative materials or assay formats that are less vulnerable to tariff volatility. Collectively, these responses are guiding a pragmatic rebalancing of cost, quality, and operational continuity across the diagnostic ecosystem.

Deep segmentation insights showing how test type, assay technologies, sample matrices, clinical settings, and applications uniquely shape adoption and product strategy

Segment-level dynamics reveal differentiated value drivers across test type, technology, sample type, end user, and application, each of which shapes clinical adoption and commercial positioning. In terms of test type, the dichotomy between laboratory-based assays and point-of-care solutions creates distinct use case pathways: centralized laboratory platforms prioritize throughput, analytic precision, and integration with laboratory information systems, while point-of-care options emphasize rapid turnaround, portability, and direct clinician-facing results. Concerning technology, chemiluminescence immunoassays frequently serve high-volume laboratories with automated workflows and enhanced sensitivity; enzyme-linked immunosorbent assays offer flexibility for specialized testing and research contexts; fluorescence immunoassays support compact, sensitive systems suitable for both near-patient and central lab deployment; and latex agglutination methods remain relevant where simplicity and cost containment are prioritized.

Sample type considerations also drive procurement and workflow choices. Plasma samples are commonly used in centralized lab workflows for their compatibility with automated analyzers and standardized processing; serum is selected in settings where coagulation control and sample stability matter; and whole blood is pivotal for point-of-care environments where immediate testing without centrifugation streamlines clinical decision-making. End user segmentation sheds light on setting-specific requirements: ambulatory surgical centers demand rapid, reliable assays that support same-day procedures and minimize cancellations; diagnostic laboratories require high-throughput, validated platforms that integrate into existing automation tracks; and hospitals need a mixture of centralized and near-patient capabilities to support emergency, inpatient, and perioperative workflows. Finally, application-driven insights emphasize clinical priorities: tests used for disseminated intravascular coagulation require robust sensitivity and dynamic range to capture coagulation abnormalities; stroke applications necessitate fast turnaround and compatibility with acute care algorithms; and venous thromboembolism evaluation benefits from high negative predictive value and standardized interpretive criteria. Taken together, these segmentation perspectives inform product design, go-to-market strategies, and clinical validation priorities for stakeholders seeking to align offerings with distinct care settings and diagnostic objectives.

Regional dynamics and market drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, regulation, and procurement strategies

Regional dynamics are pivotal in shaping demand patterns, regulatory expectations, and the competitive landscape for D-dimer testing solutions across major geographies. The Americas region is characterized by advanced clinical adoption, growing emphasis on point-of-care deployment in emergency medicine, and payer environments that increasingly require evidence of cost-effectiveness and clinical impact. Laboratories and hospitals in this region often pursue integrated solutions that link assay performance with operational efficiency, and manufacturers prioritize regulatory alignment with national standards to facilitate market access.

In Europe, Middle East & Africa, fragmentation in healthcare systems and regulatory harmonization efforts create a complex market environment. In some European markets, centralized procurement and strong laboratory infrastructures favor high-throughput laboratory assays, while other markets within the region place greater emphasis on decentralized testing due to access constraints. Regulatory pathways vary widely across the region, which affects timelines for product introduction and necessitates tailored clinical validation strategies. In many parts of the region, price sensitivity and logistics considerations influence the balance between point-of-care convenience and centralized analytical rigor.

The Asia-Pacific region is notable for rapid adoption curves, significant investments in healthcare infrastructure, and a heterogeneous mix of urban tertiary centers and rural clinics. Demand for both high-throughput laboratory platforms and affordable rapid tests is strong, driven by the need to improve acute care triage and reduce diagnostic delays. Local manufacturing and regulatory initiatives in several countries are fostering domestic production capabilities and shortening time-to-market for region-specific solutions. Across all regions, collaboration between manufacturers, clinicians, and procurement bodies is instrumental in aligning product capabilities with clinical workflows and reimbursement realities, thereby accelerating appropriate adoption and sustainable utilization.

Competitive landscape analysis emphasizing how incumbents, specialized developers, and point-of-care innovators are differentiating through technology, partnerships, and evidence generation

Competitive dynamics among established diagnostic companies, specialized assay developers, and emerging point-of-care entrants are shaping the D-dimer testing marketplace. Legacy manufacturers maintain strength through installed bases in clinical laboratories, broad reagent portfolios, and global service networks that support high-volume central testing. These incumbents leverage integration capabilities with laboratory automation and information systems as a competitive moat, while investing in incremental assay performance improvements to preserve relevance in hospital systems and reference laboratories.

At the same time, specialized assay developers and niche vendors are advancing differentiated chemistries and compact platforms that address unmet clinical needs, particularly in rapid triage and decentralized care. These players often emphasize speed-to-result, ease-of-use, and minimal sample processing as core selling points. Startups and point-of-care entrants are challenging traditional models by focusing on clinician-centric design, simplified user interfaces, and connectivity features that feed directly into electronic medical records and clinical decision support systems. Strategic partnerships, co-development agreements, and channel diversification are common tactics deployed across the competitive landscape to accelerate market penetration and to overcome regulatory and reimbursement hurdles.

Across all company types, evidence generation through clinical studies, real-world validations, and health economic assessments is a central differentiator. Firms that can demonstrate consistent analytical performance, workflow benefits, and measurable reductions in downstream imaging or hospitalization are better positioned to secure formulary placements and institutional buy-in. As the ecosystem evolves, collaboration between manufacturers and healthcare institutions on piloting new deployment models will continue to influence which companies capture long-term value.

Actionable strategic priorities for diagnostic manufacturers and healthcare providers to maximize clinical adoption, supply resilience, and commercial impact for D-dimer testing

Industry leaders should prioritize a set of actionable strategies that align commercial execution with clinical impact and operational realities. First, invest in targeted clinical evidence initiatives that quantify how specific D-dimer assays influence patient pathways, imaging utilization, and length-of-stay metrics. These studies should be context-specific and designed in collaboration with end users to ensure relevance and credibility. Second, develop flexible commercial models that reduce capital barriers for adoption, such as reagent rental agreements, outcome-linked pricing, or subscription-based access to data analytics and support services. Such models increase accessibility while aligning supplier incentives with laboratory performance and uptime.

Third, strengthen supply chain resilience by diversifying manufacturing footprints and creating contingency sourcing plans for critical reagents and components. Transparent communication with institutional buyers about lead times and risk mitigation measures will build trust and reduce procurement friction. Fourth, prioritize seamless integration with clinical workflows through interoperability with laboratory information systems and electronic health records, as well as by providing training and support that accelerates adoption. Fifth, tailor go-to-market approaches by end-user segment: hospitals will value integrated laboratory solutions and service support; diagnostic laboratories will prioritize throughput and automation compatibility; ambulatory surgical centers will seek rapid, reliable assays that minimize procedural delays.

Finally, pursue regulatory and reimbursement strategies that emphasize clinical utility and health economic benefit. Engaging early with payers and health technology assessment bodies to present robust value propositions can shorten commercialization timelines and improve uptake. By executing on these priorities, industry leaders can translate technological advantages into sustainable market positions and demonstrable improvements in patient care.

A rigorous mixed-methods research approach combining frontline stakeholder interviews, clinical literature review, and cross-validated analytical techniques to produce actionable diagnostics insights

This research synthesizes evidence from a combination of primary and secondary sources to ensure rigor and relevance. Primary inputs include stakeholder interviews with laboratory directors, clinical pathologists, emergency medicine physicians, procurement professionals, and product managers, supplemented by site visit observations to understand workflow constraints and adoption barriers. These direct engagements provide qualitative insights into real-world assay performance, turnaround time expectations, and procurement decision criteria. Secondary sources encompass peer-reviewed clinical literature, regulatory filings, device instructions for use, and publicly available clinical guidelines that inform assay utility and recommended diagnostic algorithms.

Data synthesis involved cross-validation between qualitative insights and documented evidence to identify consensus themes and to flag areas of divergence requiring further investigation. Analytical methods included comparative technology assessment, end-user mapping to clinical workflows, and scenario-based evaluation of supply-chain impacts under varying tariff conditions. Quality control measures comprised methodological triangulation, repeated stakeholder validation sessions, and internal peer review to ensure findings are robust and defensible. Limitations of the approach include variable availability of proprietary commercial data and the dynamic nature of regulatory and reimbursement landscapes, which can evolve after primary data collection.

To mitigate these limitations, the research incorporates sensitivity checks and documents assumptions underlying interpretive conclusions. Where possible, recommendations are framed to be resilient to short-term market fluctuations and to emphasize operational levers that stakeholders can control. This methodology enables practical, evidence-based insights that healthcare leaders and commercial teams can apply to decision-making around D-dimer testing strategies.

A conclusive synthesis highlighting how clinical value, operational resilience, and interoperable solutions determine long-term success in the D-dimer diagnostics ecosystem

The cumulative analysis underscores that D-dimer testing occupies a strategic intersection of clinical necessity, technological innovation, and operational decision-making. High-sensitivity assays and rapid point-of-care solutions are not mutually exclusive but complementary, enabling a tiered diagnostic approach that aligns analytical performance with care setting requirements. As payers and providers emphasize value-based care and efficient resource utilization, evidence demonstrating how D-dimer testing reduces unnecessary imaging and streamlines patient flow will be decisive in shaping adoption patterns.

Operationally, supply-chain resilience and procurement flexibility are critical enablers of uninterrupted testing capacity. Laboratories and health systems that proactively manage sourcing channels and that engage with vendors on performance-based contracting will be better positioned to maintain continuity in the face of tariff or logistic disruptions. From a competitive standpoint, companies that marry robust analytical performance with clinician-focused usability and interoperable data architectures will secure stronger institutional partnerships and adoption momentum.

In conclusion, stakeholders should view D-dimer testing not merely as a single assay but as an element within broader diagnostic pathways that require coordinated clinical, operational, and commercial strategies. The organizations that succeed will be those that can demonstrate real-world clinical value, manage supply and cost pressures pragmatically, and deliver solutions that integrate seamlessly into heterogeneous care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. D-dimer Testing Market, by Test Type

  • 8.1. Laboratory Based
  • 8.2. Point Of Care

9. D-dimer Testing Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme Linked Immunosorbent Assay
  • 9.3. Fluorescence Immunoassay
  • 9.4. Latex Agglutination

10. D-dimer Testing Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Serum
  • 10.3. Whole Blood

11. D-dimer Testing Market, by Application

  • 11.1. Disseminated Intravascular Coagulation
  • 11.2. Stroke
  • 11.3. Venous Thromboembolism

12. D-dimer Testing Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals

13. D-dimer Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. D-dimer Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. D-dimer Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States D-dimer Testing Market

17. China D-dimer Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Beckman Coulter, Inc.
  • 18.7. bioMerieux SA
  • 18.8. DiaSorin S.p.A
  • 18.9. Instrumentation Laboratory Company
  • 18.10. Ortho Clinical Diagnostics Inc.
  • 18.11. Roche Diagnostics GmbH
  • 18.12. Siemens Healthineers AG
  • 18.13. Sysmex Corporation
  • 18.14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL D-DIMER TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL D-DIMER TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL D-DIMER TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL D-DIMER TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL D-DIMER TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL D-DIMER TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL D-DIMER TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL D-DIMER TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL D-DIMER TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL D-DIMER TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL D-DIMER TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL D-DIMER TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL D-DIMER TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL D-DIMER TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL D-DIMER TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL D-DIMER TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL D-DIMER TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL D-DIMER TESTING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL D-DIMER TESTING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL D-DIMER TESTING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL D-DIMER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL D-DIMER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL D-DIMER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL D-DIMER TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL D-DIMER TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL D-DIMER TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL D-DIMER TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL D-DIMER TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL D-DIMER TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL D-DIMER TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL D-DIMER TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL D-DIMER TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL D-DIMER TESTING MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL D-DIMER TESTING MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL D-DIMER TESTING MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL D-DIMER TESTING MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL D-DIMER TESTING MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL D-DIMER TESTING MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL D-DIMER TESTING MARKET SIZE, BY VENOUS THROMBOEMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL D-DIMER TESTING MARKET SIZE, BY VENOUS THROMBOEMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL D-DIMER TESTING MARKET SIZE, BY VENOUS THROMBOEMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL D-DIMER TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL D-DIMER TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL D-DIMER TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL D-DIMER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL D-DIMER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL D-DIMER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL D-DIMER TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL D-DIMER TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL D-DIMER TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL D-DIMER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS D-DIMER TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL D-DIMER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. GCC D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. GCC D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GCC D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. G7 D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. NATO D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NATO D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL D-DIMER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA D-DIMER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA D-DIMER TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA D-DIMER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA D-DIMER TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA D-DIMER TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA D-DIMER TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)